导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.37% | 3242/4773 |
| 近一周 | -0.75% | 245/5462 |
| 近一月 | 1.69% | 325/5421 |
| 近一季 | 2.13% | 491/5209 |
| 近半年 | -3.30% | 2172/4920 |
| 近一年 | -4.83% | 3134/4366 |
| 近两年 | 22.16% | 2604/2954 |
| 近三年 | 17.60% | 1565/2253 |
| 成立以来 | 116.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.13% 3538/4961 |
-8.78% 3916/5312 |
- - |
- - |
| 2025 | 4.48% 3046/4813 |
-2.63% 2934/3635 |
5.50% 579/4076 |
-0.57% 3928/4524 |
2.29% 1010/4813 |
| 2024 | 28.30% 157/3463 |
7.91% 214/2808 |
2.98% 292/3014 |
16.10% 1534/3129 |
-0.56% 1463/3463 |
| 2023 | 0.46% 410/2656 |
4.64% 896/2280 |
2.18% 158/2385 |
2.03% 260/2515 |
-7.92% 2223/2655 |
| 2022 | -2.38% 57/2207 |
-1.01% 136/1919 |
1.68% 1437/2016 |
-6.69% 106/2113 |
3.94% 616/2208 |
| 2021 | -1.61% 812/1822 |
3.33% 184/1255 |
-4.48% 1261/1330 |
-0.72% 502/1466 |
0.40% 1121/1822 |
| 2020 | 2.86% 914/1250 |
-12.93% 908/1028 |
1.38% 988/1067 |
8.14% 730/1164 |
7.76% 696/1184 |
| 2019 | 21.37% 650/1092 |
15.82% 678/754 |
1.41% 128/804 |
-1.54% 664/850 |
4.95% 764/918 |
| 2018 | -12.79% 84/834 |
- - |
- - |
- - |
-9.67% 157/691 |
| 2017 | 28.12% 81/714 |
- - |
- - |
- - |
- - |
| 2016 | 3.87% 79/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.21% 223/575 |
- - |
- - |
- - |
- - |
| 2014 | 77.24% 11/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.82% 161/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.28% 34/140 |
- - |
- - |
- - |
- - |
| 2011 | -14.56% 5/102 |
- - |
- - |
- - |
- - |
| 2010 | -26.11% 58/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实基本面50指数(LOF)A VS. 长安沪深300非周期A(740101) |